RESULTS: There were 286 (0.06%) occurrences of SBO out of 47,937 hysterectomies. Patients experiencing SBO were more likely to undergo abdominal hysterectomy (72.0% vs 21.2%, p<0.001), LOA (5.2% vs 2.1%, p<0.001), appendectomy (1.7% vs 0.5%, p¼0.02), and cystotomy repair (1.0% vs 0.3%, p¼ 0.002). After logistic regression, mode of hysterectomy was not a significant predictor of SBO, while contaminated and infected wounds (aOR¼5.93, 95% CI: 2.71-12.96) and perioperative transfusion (aOR¼5.21, 95% CI: 3.66-7.29) were the most significant risk factors. Additional risk factors for early SBO included non-white race (aOR¼ 1.83, 95% CI: 1.34-2.48), older age (aOR¼1.03, 95% CI: 1.02-1.05), prior abdominal or pelvic surgery (aOR¼1.45, 95% CI: 1.26-2.60), operating times exceeding 170 minutes (aOR¼1.90, 95% CI: 1.39-2.59), uterine weight greater than 250 grams (aOR¼1.54, 95% CI: 1.11-2.14), lysis of adhesions (aOR¼2.12, 95% CI: 1.24-3.66), and concurrent appendectomy (aOR¼2.98, 95% CI: 1.20-7.41). CONCLUSION: Early small bowel obstruction is a rare complication of benign hysterectomy and is unrelated to route of hysterectomy after adjusting for confounders. Multiple risk factors related to abdomino-pelvic adhesive disease were associated with a higher risk of bowel obstruction.
OBJECTIVES: To determine if cerebral small vessel ischemic disease (SVID) affects the rate of response to antimuscarinic medications for treating overactive bladder (OAB) symptoms.
MATERIALS AND METHODS:
This retrospective matched-cohort of patients treated for OAB with antimuscarinics between January 2010 and December of 2017. Patients were included if they had never been evaluated by a urogynecologist in the past with a chief complaint related to OAB were included and were treated with a maximum effective dose of an antimuscarinic for a minimum of 4 weeks and underwent head computed tomography (CT) within 12 months of starting therapy. All patients had to have explicit documentation of treatment adherence and whether there was a satisfactory therapeutic response. Patients with SVID were matched 1:1 by age and number of prior failed antimuscarinics to controls with normal head CTs. Exclusion criteria included incomplete documentation of adherence or therapeutic response, non-SVID CT abnormalities, OAB symptoms occurring within 6 months of pelvic surgery, genitourinary malignancy, evidence of urinary retention, and neurogenic bladder. The primary outcome was antimuscarinic treatment failure. Pairwise analysis between groups was performed using Wilcoxon Rank-Sum and Fisher's exact test where appropriate. Univariate logistic regression was performed and any variable that was associated with treatment failure and a p-value 0.2 was included in the multivariable regression analysis. RESULTS: A total of 68 cases were matched with 68 controls. Table 1 shows the demographic characteristics of the two groups and table 2 shows the clinical characteristics. There were no significant differences between the two groups except that patients with SVID were more likely to have undergone hysterectomy, 57.4% vs 41.2%, p¼0.04. Patients with SVID were more likely to fail antimuscarinic treatment compared to controls (60.7% vs 29.4%, p¼0.004). After adjusting for confounders, SVID was strongly associated with an increased probability of failure (aOR¼ 4.19, 95% CI: 1.78-9.81). An active diagnosis of anxiety or depression (aOR ¼ 2.70, 95% CI: 1.15-6.33) and increasing number of daily urgency incontinence episodes (aOR ¼ 1.32 per episode, 95% CI: 1.08-1.61) were also associated with treatment failure. CONCLUSION: SVID is independently associated with anti-muscarinic treatment failure in women with overactive bladder symptoms.
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OBJECTIVES:
The primary objective of this study was to describe our experience with unilateral sacrospinous ligament hysteropexy (SSLH) performed via an incision through the anterior vaginal wall for treatment of uterovaginal prolapse. Additionally, we sought to identify factors associated with symptomatic recurrence. MATERIALS AND METHODS: An IRB approved retrospective chart review was performed identifying women who underwent SSLH (CPT code 57282) from January 2013 to March 2017 performed at the University of Rochester Medical Center. Subjects were excluded if graft augmentation was used, they had a prior hysterectomy, or if bilateral suspension was performed. Demographics, comorbidities, and perioperative data were extracted from the electronic medical records. Descriptive statistics were performed and data were compared between subjects who felt their prolapse symptoms were resolved and those who felt they recurred using t test, Wilcoxon rank sum test, chi-square test, or fisher exact test as appropriate. RESULTS: The cohort (n ¼ 59) consisted of predominantly white (93%), non-smoking (54%), post-menopausal women (92%) with private insurance (59%). Median age was 63 years (range, 43 e 80 years), median body mass index (BMI) was 26.8 kg/m 2 (range, 18.9 e 43.1 kg/m 2 ), and median pelvic organ prolapse quantification (POPQ) stage was 3 (range, 2 e 3) at the time of surgery. The median operative time was 80 mins (IQR: 67, 94.5 mins) including concomitant anterior (n ¼ 49), enterocele (n ¼ 1), and/or posterior repairs (n ¼ 12). Concomitant retropubic sling was performed in 3 subjects. Median estimated blood loss (EBL) was 50 mL (IQR: 25, 50 mL) and median time in the post-anesthesia care unit (PACU) was 72 min (IQR: 57, 101 mins). The average milligram morphine equivalents (MME) administered in PACU was 2.1 AE 3.1 MME. Most women (81%) were discharged home on the day of surgery. We observed a recurrence rate of 25.4% which was not significantly associated with surgeon (p ¼ 0.23), subject's age (p ¼ 0. Postoperative complications included urinary retention (n ¼ 2), de novo stress urinary incontinence (n ¼ 2), and urinary tract infection (n ¼ 4). Nineteen subjects admitted to buttock pain in the first week after surgery, 4 requested additional narcotic medication, and 1 had a suture release due to persistent pain. CONCLUSION: Unilateral sacrospinous ligament hysteropexy is a welltolerated treatment option for uterovaginal prolapse. The suspension is an efficient and effective procedure when performed through the anterior vaginal wall with a low incidence of complications and a recurrence rate of 25%.
